AZ’s cancer drug fails again, Roche’s rival gets new useAstraZeneca’s immunotherapy Imfinzi has failed in another late stage study, while Roche’s rival Tecentriq combination has been approved Share XAZ’s cancer drug fails again, Roche’s rival gets new usehttps://pharmaphorum.com/news/azs-cancer-imfinzi-fail/
AbbVie suffers fresh setback with lung cancer drug Rova-TAbbVie has suffered a further setback with its oncology drug Rova-T, after early data from a lung cancer Share XAbbVie suffers fresh setback with lung cancer drug Rova-Thttps://pharmaphorum.com/news/abbvie-suffers-fresh-setback-with-lung-cancer-drug-rova-t/
Thousands to benefit as NHS funds Keytruda lung cancer comboNICE has said MSD’s cancer immunotherapy, Keytruda, should receive interim funding on the NHS in certain patients with Share XThousands to benefit as NHS funds Keytruda lung cancer combohttps://pharmaphorum.com/news/thousands-to-benefit-as-nhs-funds-keytruda-lung-cancer-combo/
AstraZeneca’s immunotherapy fails in key lung cancer trialAstraZeneca’s immunotherapy combination including its checkpoint inhibitor drug Imfinzi has failed to improve overall survival in a first-line Share XAstraZeneca’s immunotherapy fails in key lung cancer trialhttps://pharmaphorum.com/news/astrazenecas-imfinzi-fails-in-key-lung-cancer-trial/
J&J buys novel lung cancer drug from South Korea’s YuhanJanssen Biotech has bought Yuhan’s Lazertinib, a novel clinical-stage therapeutic candidate for the treatment of patients with non-small Share XJ&J buys novel lung cancer drug from South Korea’s Yuhanhttps://pharmaphorum.com/news/jj-buys-novel-lung-cancer-drug-from-south-koreas-yuhan/
FDA green lights Pfizer’s Lorbrena for aggressive lung cancerPfizer’s drug Lorbrena (lorlatinib) can be used to treat certain types of advanced lung cancer. The US Food Share XFDA green lights Pfizer’s Lorbrena for aggressive lung cancerhttps://pharmaphorum.com/news/fda-green-lights-pfizers-lorbrena-for-aggressive-lung-cancer/
ESMO round-up: Big win for AstraZeneca in ovarian cancer, and moreSeveral drugmakers announced significant trial findings at this week’s European Society for Medical Oncology (ESMO) conference in Munich. Share XESMO round-up: Big win for AstraZeneca in ovarian cancer, and morehttps://pharmaphorum.com/views-and-analysis/esmo-round-up-big-win-for-astrazeneca-in-ovarian-cancer-and-more/
Roche’s Tecentriq posts trial wins in two key indicationsRoche has scored two big wins with its Tecentriq cancer immunotherapy at ESMO in tough to treat triple Share XRoche’s Tecentriq posts trial wins in two key indicationshttps://pharmaphorum.com/news/roches-tecentriq-posts-trial-wins-in-two-key-indications/
BMS Opdivo fails in small cell lung cancerBristol-Myers Squibb has said its Opdivo immunotherapy has failed to improve on standard of care in patients with Share XBMS Opdivo fails in small cell lung cancerhttps://pharmaphorum.com/news/bms-opdivo-fails-in-small-cell-lung-cancer/
